10-K: Roivant Sciences Reports Fiscal Year 2025 Net Loss Amid Increased R&D and Strategic Pipeline Advancement

Roivant Sciences Ltd. reported a net loss of $356.7 million for fiscal year 2025, primarily due to increased operating expenses and the absence of a large one-time gain from the prior year's Telavant divestiture, despite significant clinical progress across its diverse biopharmaceutical pipeline.

Summary

• Roivant Sciences Ltd. reported a net loss of $356.734 million for the fiscal year ended March 31, 2025, a significant shift from the net income of $4,231.206 million in the prior fiscal year.
• The company's cash, cash equivalents, and marketable securities totaled approximately $4.9 billion as of March 31, 2025.
• Operating expenses increased by $258.643 million to $1,142.734 million for FY2025, driven by higher research and development (R&D) and general and administrative (G&A) expenses.
• R&D expenses rose by $110.504 million to $550.413 million in FY2025, reflecting progression of programs like the anti-FcRn franchise and mosliciguat, partially offset by the sale of RVT-3101.
• G&A expenses increased by $175.277 million to $591.410 million in FY2025, largely due to increased share-based compensation and personnel-related expenses from the 2024 Senior Executive Compensation Program.
• Roivant completed the sale of Dermavant to Organon in October 2024 for aggregate consideration of up to approximately $1.2 billion, including an upfront payment of $175 million and a $75 million milestone payment received in January 2025 for FDA approval of VTAMA for atopic dermatitis.
• The company repurchased 128 million common shares for $1.3 billion in fiscal year 2025, reducing common shares outstanding by 14% from March 31, 2024.
• Positive Phase 2 NEPTUNE study results were reported for once-daily oral brepocitinib in non-infectious uveitis, showing potential best-in-indication results on median time to treatment failure (>12 months for 45mg dose).
• A Phase 3 program for brepocitinib in non-infectious uveitis was initiated, with topline data expected in 1H 2027, and a Phase 2 study in cutaneous sarcoidosis was initiated, with topline data expected in 2H 2026.
• Enrollment was completed for the ongoing Phase 3 study of brepocitinib in dermatomyositis, with topline data expected in 2H 2025.
• Top-line Phase 3 results for batoclimab in myasthenia gravis met its primary endpoint, demonstrating a 5.6 point mean improvement in MG-ADL and a 93% response rate for the 680mg weekly SC injection dose.
• Additional positive results from the Phase 2a trial of batoclimab in Graves disease showed a mean IgG reduction of 77% and a 76% response rate with the 680mg dose.
• Six Investigational New Drug (IND) applications were cleared for IMVT-1402, with studies initiated in five indications, including potentially registrational trials in Graves disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
• The new pipeline program mosliciguat, an inhaled sGC activator, showed clinically meaningful mean-max reductions in pulmonary vascular resistance of up to approximately 38% in its Phase 1b ATMOS study.
• A Phase 2 PHocus study of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) was initiated, with topline data expected in 2H 2026.
• The company continued patent infringement litigation against Moderna and Pfizer/BioNTech in the United States and initiated five international enforcement actions against Moderna across 30 countries.

Sentiment

Score: 6

Explanation: The company reported a significant net loss for the fiscal year, primarily due to the absence of a large one-time gain from the prior year's divestiture and increased operating expenses. However, the underlying business shows strong clinical progress with multiple positive trial results and pipeline advancements, indicating potential future value. The financial position remains strong with substantial cash reserves, but future profitability is uncertain and dependent on successful commercialization. The ongoing patent litigation and potential regulatory changes add a layer of uncertainty.

Positives

• Successfully completed the sale of Dermavant to Organon for aggregate consideration of up to approximately $1.2 billion, including an upfront payment of $175 million and a $75 million milestone payment received in January 2025.
• Executed a significant share repurchase program, buying back 128 million common shares for $1.3 billion in FY2025, reducing outstanding shares by 14%.
• Reported positive Phase 2 results for brepocitinib in non-infectious uveitis, demonstrating potential best-in-indication results on median time to treatment failure and meaningful improvements in other measurements.
• Initiated Phase 3 development for brepocitinib in non-infectious uveitis and a Phase 2 study in cutaneous sarcoidosis, expanding its clinical reach.
• Completed enrollment for the Phase 3 study of brepocitinib in dermatomyositis, moving closer to potential topline data.
• Achieved positive top-line Phase 3 results for batoclimab in myasthenia gravis, meeting its primary endpoint and setting a new benchmark for magnitude of benefit with a 5.6 point mean improvement and 93% response rate.
• Reported additional positive Phase 2a results for batoclimab in Graves disease, showing strong IgG reduction (77%) and response rates (76%).
• Cleared six INDs for IMVT-1402 and initiated studies in five indications, including multiple potentially registrational trials, indicating rapid pipeline advancement.
• Announced promising Phase 1b data for mosliciguat, showing significant reductions in pulmonary vascular resistance (up to 38%), representing some of the highest reductions seen in PH trials to date.
• Initiated a Phase 2 study for mosliciguat in PH-ILD, targeting a large, well-validated market with limited approved treatments.
• Actively pursuing and expanding patent infringement litigation against major pharmaceutical companies (Moderna, Pfizer/BioNTech) in multiple jurisdictions, potentially securing significant future value from its LNP technology.
• Maintained a strong cash, cash equivalents, and marketable securities position of approximately $4.9 billion, providing substantial liquidity for future operations and strategic initiatives.
• Management concluded that disclosure controls and procedures and internal control over financial reporting were effective as of March 31, 2025.

Negatives

• Reported a net loss of $356.734 million for the fiscal year ended March 31, 2025, a substantial decrease from the $4,231.206 million net income in the prior year.
• Loss from continuing operations significantly increased to $1,003.294 million in FY2025 from a gain of $4,497.032 million in FY2024, primarily due to the absence of the large one-time gain from the Telavant divestiture.
• Operating expenses increased by $258.643 million, driven by higher R&D and G&A costs, indicating increasing burn rate.
• The company has a relatively limited operating history and no commercial-stage product following the Dermavant sale, leading to an expectation of significant operating losses for the foreseeable future and no guarantee of sustained profitability.
• Cash used in operating activities increased by $74.2 million to $839.5 million in FY2025.
• Incurred an unrealized loss of $55.186 million on the fair value of investments in FY2025.
• The company faces inherent uncertainties and risks in biopharmaceutical product development and commercialization, with no assurance that product candidates will achieve regulatory approval or commercial viability.
• There is no assurance that the company will receive all future milestone or royalty payments owed from the Dermavant Transaction.
• The company may require additional capital in the future to fund operations, which could lead to substantial dilution for existing shareholders.
• The Vant structure, while offering advantages, also poses risks such as increased costs, potential for value concentration in a few Vants, and limited operational control over non-wholly-owned subsidiaries.
• The company is exposed to risks related to its significant holdings of cash, cash equivalents, and marketable securities, including market volatility and potential bank failures.
• Drug discovery efforts may not be successful in identifying new product candidates, and internally discovered candidates may not advance to clinical trials or regulatory approval.
• Clinical trials are very expensive, time-consuming, difficult to design, and involve uncertain outcomes, with potential for substantial delays or failures.
• The results of preclinical and early clinical trials may not be predictive of future trial results, and interim data are subject to change.
• Product candidates may cause undesirable side effects, potentially halting development or limiting approval/market acceptance.
• Reliance on third parties for clinical trials and manufacturing introduces risks of unsatisfactory performance, non-compliance, and supply chain disruptions.
• The company is highly dependent on key personnel and faces intense competition for talent.
• The use of AI in its businesses could expose the company to liability or adversely affect operations due to flaws, bias, or evolving regulatory frameworks.
• Challenges in obtaining and maintaining intellectual property protection, including ongoing patent litigation, could be expensive and time-consuming, and may not result in favorable outcomes.
• The length of patent terms may be inadequate to protect the competitive position of product candidates for a sufficient time.
• Operating as a public company incurs increased costs and management time for compliance.
• Anti-takeover provisions and significant control by largest shareholders could limit other investors' influence.
• Future sales or the perception of future sales of common shares by the company or existing shareholders could cause the market price to decline.
• No plans to pay cash dividends in the foreseeable future, meaning investors may only see returns through share price appreciation.
• Bermuda incorporation may make it difficult for U.S. investors to enforce judgments.
• Potential for unanticipated tax liabilities and higher effective tax rates due to complex international tax laws and potential challenges to transfer pricing.
• Risk of being characterized as a Controlled Foreign Corporation (CFC) or Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. holders.
• The company faces significant competition from established pharmaceutical and biotechnology companies.
• Healthcare legislative and regulatory measures aimed at reducing costs (e.g., Inflation Reduction Act, state-level pricing controls) could adversely affect pricing and reimbursement for future products.
• Potential for reimportation of drugs from foreign countries could decrease prices.
• Operational risks associated with the physical and digital infrastructure of manufacturing facilities, including cybersecurity threats, could disrupt operations.

Risks

• The company has a relatively limited operating history and no commercial-stage product following the Dermavant sale, making it difficult to assess future prospects and likely leading to significant operating losses for the foreseeable future.
• The company may not be successful in acquiring or in-licensing new product candidates, or newly acquired candidates may not perform as expected in clinical trials or achieve marketing approvals.
• Significant operating losses are expected for the foreseeable future, and the company may never achieve sustained profitability.
• The allocation of capital and personnel across the company's diverse businesses (Vants) carries risks, including potentially missing valuable opportunities or misinterpreting industry trends.
• The 'Vant' structure, while offering advantages, also poses risks such as increased costs, potential for a large proportion of value/revenue from a single Vant, and limitations on operational control over non-wholly-owned Vants.
• The company faces risks associated with potential future milestone and royalty payments owed in connection with its in-licensed product candidates, which could be substantial and impact profitability.
• Acquisitions, divestitures, and other strategic transactions (like the Dermavant sale) entail risks, including the failure to realize expected benefits or the inability of counterparties to meet obligations.
• Significant holdings of cash, cash equivalents, and marketable securities are exposed to risks from changes in liquidity, market conditions, interest rate fluctuations, and credit risk.
• While currently liquid, the company may require additional capital in the future to fund operations, and failure to obtain necessary financing could delay or terminate development and commercialization efforts.
• The company's business strategy and growth rely on assumptions that may not be realized, particularly regarding therapy approval, market adoption, and patient populations.
• Drug discovery efforts, especially those using computational tools, may not successfully identify new product candidates or advance them through clinical trials.
• Unfavorable, uncertain, and rapidly changing global and regional economic, political, and public health conditions (e.g., inflation, geopolitical conflicts, trade disputes, disease outbreaks) could adversely affect the business.
• Inadequate funding for U.S. government agencies like the FDA, USPTO, and SEC could hinder or delay their operations, impacting regulatory processes.
• Clinical trials and preclinical studies are very expensive, time-consuming, difficult to design, and involve uncertain outcomes, with substantial delays or failures possible at any stage.
• Difficulties in enrolling and retaining patients in clinical trials could delay or adversely affect clinical development activities.
• Results of preclinical studies and earlier clinical trials may not be predictive of future trial results, and interim data are subject to material changes.
• Changes in product manufacturing or formulation methods may result in additional costs or delays.
• Obtaining new drug approval is an extensive, lengthy, expensive, and inherently uncertain process, and regulatory authorities may delay, limit, or deny approval.
• Clinical trials may fail to demonstrate substantial evidence of safety and efficacy, preventing or limiting regulatory approval and commercialization.
• Product candidates may cause undesirable side effects or have other properties that could halt development, delay approval, limit labeling, or result in negative consequences.
• Regulatory approval processes vary widely by country, and approval in one jurisdiction does not guarantee approval or commercialization in others.
• Reliance on third parties (CROs, CMOs) to conduct, supervise, and monitor clinical trials and produce supplies carries risks of unsatisfactory performance or non-compliance.
• High dependence on key personnel, and inability to attract, motivate, and retain highly qualified individuals could hinder business strategy implementation.
• The use of artificial intelligence (AI) could expose the company to liability or adversely affect its business due to flaws, bias, ethical issues, or evolving regulatory frameworks.
• Inability to obtain and maintain patent and other intellectual property protection, or insufficient breadth of protection, could impair competitive effectiveness.
• Patent applications may fail to issue, or their validity, patentability, enforceability, breadth, or strength of protection may be threatened, dissuading collaborations and threatening commercialization.
• The length of patent terms may be inadequate to protect the competitive position of product candidates for a sufficient amount of time.
• The company is subject to litigation and investigation risks, including patent infringement lawsuits (e.g., against Moderna and Pfizer/BioNTech), product liability claims, and regulatory proceedings, which could be costly and divert resources.
• Internal computer and information technology systems, or those of third parties, may fail or suffer cyberattacks or security breaches, compromising data and exposing the company to liability.
• The business is subject to complex and evolving U.S. and foreign laws and regulations relating to privacy and data protection, with potential for claims, penalties, and business disruption.
• Failure by employees, contractors, or third parties to comply with healthcare laws or regulatory standards could lead to substantial penalties.
• Product liability claims related to product candidates could result in substantial liabilities, delays in trials, and limits on commercialization.
• Non-compliance with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Adverse effects from earthquakes, hurricanes, fires, disease outbreaks, or other natural disasters could disrupt operations.
• The increasing use of social media platforms presents new risks and challenges, including potential non-compliance with regulations and negative publicity.
• If the company's performance does not meet market expectations, the price of its securities may decline due to various market and industry factors.
• Operating as a public company incurs increased costs and requires substantial management time for compliance initiatives.
• Failure to maintain proper and effective internal control over financial reporting could impair the ability to produce accurate financial statements and erode investor confidence.
• Anti-takeover provisions in the company's organizational documents and Bermuda law could delay or prevent a change in control and entrench management.
• Largest shareholders own a significant percentage of common shares and can exert substantial control over matters subject to shareholder approval, potentially misaligning with other shareholders' interests.
• Future sales and issuances of equity securities by the company or its Vants will result in additional dilution of percentage ownership and could cause the share price to fall.
• Future sales, or the perception of future sales, of common shares by the company or existing shareholders could cause the market price to decline and impact future capital raising ability.
• Negative evaluations by securities analysts could cause the price of common shares to decline.
• No plans to pay cash dividends for the foreseeable future means investors may not receive any return on investment unless they sell shares for a price greater than paid.
• As a Bermuda-incorporated company, it may be difficult for U.S. investors to enforce judgments against the company or its directors and executive officers.
• Bermuda law differs from U.S. law and may afford less protection to shareholders.
• Regulatory limitations exist on the ownership and transfer of common shares in Bermuda.
• The company may become subject to unanticipated tax liabilities and higher effective tax rates due to complex international tax laws and potential challenges to transfer pricing.
• U.S. holders owning 10% or more of common shares may suffer adverse tax consequences if the company or its non-U.S. subsidiaries are characterized as controlled foreign corporations (CFCs) or a passive foreign investment company (PFIC).

Future Outlook

Roivant expects to incur substantial operating losses for the foreseeable future as it advances its product candidates through preclinical studies and clinical trials and pursues potential commercialization. Research and development expenses are anticipated to increase, as are general and administrative expenses to support commercialization efforts. The company plans to continue in-licensing new mid/late-stage drugs annually. Key upcoming catalysts include additional Graves disease data for batoclimab (Summer 2025), topline data for brepocitinib in dermatomyositis (2H 2025) and non-infectious uveitis (1H 2027), topline data for batoclimab in thyroid eye disease (2H 2025), and topline data for mosliciguat in PH-ILD (2H 2026). Initial results for IMVT-1402 in difficult-to-treat rheumatoid arthritis and topline data in cutaneous lupus erythematosus are expected in 2026, with further registrational trial data for IMVT-1402 in Graves disease, myasthenia gravis, Sjogren's disease, and chronic inflammatory demyelinating polyneuropathy expected in 2027-2028. The timing of ongoing patent litigation against Moderna and Pfizer/BioNTech remains subject to court updates. While the company believes its current cash position is sufficient for the foreseeable future, it acknowledges that projections are uncertain and additional capital may be required.

Management Comments

• "Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter."
• "The Vant model unlocks key strategic advantages for Roivant and, we believe, ultimately enables us to develop transformative medicines for diseases for which there are no approved therapies or where the current standard of care treatment has significant limitations faster than our competitors."
• "We plan to be laser-focused on clinical execution to maintain our head start in the indications listed above and to be nearly-first and best-in-class for indications such as SjD where we are close from a timing perspective to in-class competition and expect a differentiated clinical profile."
• "Management expects to incur additional losses in the future to fund its operations and conduct product research and development and may require additional capital to fully implement its business plan."
• "We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditures for the foreseeable future."
• "Our management team has broad discretion in respect of use of our cash, cash equivalents and marketable securities."
• "Our management... concluded that our disclosure controls and procedures were effective as of March 31, 2025."
• "Our management has assessed the effectiveness of our internal control over financial reporting as of March 31, 2025... and concluded that... our internal control over financial reporting was effective."

Industry Context

The biopharmaceutical industry is highly competitive, characterized by significant upfront investments, lengthy development timelines, and high regulatory hurdles. Roivant operates within this landscape by leveraging its 'Vant' model, which aims to accelerate drug development through nimble, entrepreneurial subsidiaries. The company faces competition from major pharmaceutical and biotechnology firms, as well as emerging players in healthcare technology and computational drug discovery. The industry is also heavily influenced by evolving healthcare legislation and regulatory measures, such as the Inflation Reduction Act in the U.S. and new EU pharmaceutical strategies, which aim to control drug pricing and increase accessibility. The increasing adoption of AI in drug discovery introduces new competitive dynamics and regulatory complexities. Roivant's focus on in-licensing promising drug candidates and maintaining a diversified pipeline is a strategy to mitigate the inherent risks of drug development and compete effectively in this dynamic environment.

Comparison to Industry Standards

• Roivant's 'Vant' model is designed to facilitate rapid decision-making and calculated risk-taking, aiming to develop transformative medicines faster than competitors, in contrast to traditional pharmaceutical companies.
• The company boasts an impressive track record since its founding in 2014, having received 8 FDA approvals and completed 12 large registrational Phase 3 studies, with the last 11 yielding positive data, suggesting a higher success rate in late-stage development compared to typical industry averages.
• Brepocitinib's Phase 2 NEPTUNE study in non-infectious uveitis demonstrated 'potential best-in-indication results on median time to treatment failure' compared to other active NIU studies measuring this registrational endpoint.
• Batoclimab's Phase 3 study in myasthenia gravis 'set a new benchmark for magnitude of benefit' with a 5.6 point mean improvement and 93% MG-ADL Response Rate, surpassing the typical 60-70% IgG reduction observed with other approved FcRn inhibitors in their Phase 3 trials.
• IMVT-1402 is expected to achieve 'approximately 80% IgG reductions,' offering 'deeper IgG reductions than observed with other competitor anti-FcRn programs,' positioning it as a potentially best-in-class candidate.
• Mosliciguat's Phase 1b ATMOS study showed 'mean-max reductions in pulmonary vascular resistance (PVR) of up to approximately 38%,' which 'represent some of the highest reductions seen in PH trials to date,' indicating strong efficacy compared to existing treatments like inhaled treprostinils (Tyvaso, Yutrepia).
• Genevant's LNP technology 'outperformed all third-party formulations tested in a head-to-head in vivo ionizable lipid study assessing LNP potency and immune stimulation,' highlighting its superior performance in nucleic acid delivery.

Management Changes

Corporate Governance

Legal Proceedings

• Continued patent infringement litigation against Moderna and Pfizer/BioNTech in the United States.
• Initiated five patent infringement enforcement actions against Moderna outside of the United States, targeting alleged infringing activities in 30 countries.
• The court in the U.S. Moderna case plans to update the timing for the summary judgment phase and jury trial, previously scheduled for 2Q/3Q 2025 and September 2025, respectively.
• A Markman hearing was held in the Pfizer/BioNTech case in December 2024, with a ruling potentially expected in calendar year 2025.
• Genevant's European patent (EP2279254) relating to lipid nanoparticle molar ratios is subject to an ongoing opposition proceeding at the European Patent Office (EPO) Opposition Division, with appeals pending.
• The company is subject to various litigation matters and claims arising in the ordinary course of business, including regulatory proceedings, administrative proceedings, product liability claims related to clinical trials, securities litigation, and governmental investigations.
• Several drug manufacturers have commenced litigation challenging the legality of contract pharmacy arrangements under the 340B Drug Discount Program.
• Various hospitals sued HRSA in November 2023 to challenge an agency policy requiring child sites of a hospital to be included on its most recent Medicare cost report to qualify for 340B discounts.
• Several manufacturers announced an intention to adopt a rebate model for 340B pricing, leading to HRSA objection and subsequent lawsuits by manufacturers against HRSA.
• There are several ongoing legal challenges to the Inflation Reduction Act's drug price negotiation program.
• Amgen's suit challenging the legality of the Colorado Prescription Drug Affordability Board's (PDAB) efforts to set a Upper Payment Limit (UPL) for ENBREL was dismissed without prejudice in March 2025 for lack of standing.
• In March 2025, the Eastern District of Texas vacated the FDA's final rule that would have revised the regulatory definition of an in vitro diagnostic product to explicitly capture laboratory developed tests.

Related Party Transactions

• Immunovant's license agreement with HanAll Biopharma Co., Ltd. (HanAll) for the anti-FcRn franchise, involving potential milestone and royalty payments.
• Priovant's license and collaboration agreement with Pfizer for brepocitinib, involving sales milestone and tiered royalty payments.
• Pulmovant's license agreement with Bayer Aktiengesellschaft for mosliciguat, involving development, regulatory, and sales milestone events, as well as tiered royalties.
• Genevant's cross-license agreement with Arbutus Biopharma Corporation (Arbutus) for LNP and GalNAc technologies, involving tiered royalties on sales and a percentage of Royalty-Related Receipts from sublicenses/collaborations.
• The company holds equity method investments in Arbutus (20% ownership) and Datavant (9% ownership), which are considered related parties.
• The sale of Telavant, jointly formed by the company and Pfizer, to Roche Holdings, Inc. in December 2023, with the company receiving a pro rata portion of the consideration.
• The sale of Proteovant Sciences, Inc. to SK Biopharmaceuticals Co., Ltd. (a subsidiary of SK, Inc.) in August 2023.
• VantAI Holdings, Inc. completed a transaction with SK, Inc. in July 2023, leading to its deconsolidation and the company retaining an equity method investment.
• The company repurchased all 71,251,083 common shares held by Sumitomo Pharma Co., Ltd. for approximately $648.4 million in April 2024, pursuant to a share repurchase agreement.
• In January 2025, Immunovant issued 22,500,000 shares of its common stock in a private placement (IMVT PIPE), of which the company purchased 16,845,010 shares for $336.9 million.
• Rakhi Kumar, former Chairman, entered into a Separation and Mutual Release Agreement and a Consulting Agreement with the company upon her employment termination in March 2025.
• Matthew Gline (Chief Executive Officer), Mayukh Sukhatme (President and Chief Investment Officer), and Eric Venker (President and Chief Operating Officer) were approved for a multi-year incentive compensation program in July 2024, including one-time cash retention awards and long-term equity incentive awards.

Stakeholder Impact

• **Shareholders**: Experienced a net loss in FY2025, but benefited from a significant share repurchase program reducing dilution. Future returns depend on successful pipeline development and commercialization, as no cash dividends are planned. Subject to dilution from future equity issuances and Vant equity plans. Impacted by outcomes of patent litigation and regulatory changes.
• **Employees**: Benefited from competitive compensation, including a special one-time cash retention bonus and long-term equity incentive awards for senior executives. Opportunities for career progression within the Vant model. Subject to potential workforce restructuring (e.g., at FDA) that could indirectly affect the industry.
• **Patients/Healthcare Providers**: Stand to benefit from the development of new, potentially transformative medicines for diseases with high unmet needs (e.g., dermatomyositis, non-infectious uveitis, Graves disease, PH-ILD). Access to these therapies is contingent on successful clinical trials and regulatory approvals. Impacted by evolving healthcare policies and reimbursement landscapes.
• **Suppliers/Contract Manufacturers**: The company continues to rely heavily on third-party contract research organizations (CROs) and contract manufacturing organizations (CMOs) for its R&D and production needs, indicating ongoing business opportunities. However, they are subject to strict quality standards and potential supply chain disruptions.
• **Creditors**: The company's ability to meet its financial obligations, including potential milestone payments under license agreements and commitments to manufacturers, depends on its future financial performance and access to capital. The repayment of Dermavant's senior secured credit facility upon its sale reduced debt obligations.

Next Steps

• Ongoing new mid/late-stage in-licensing announcements.
• Immunovant expects to report additional remission data from the Phase 2 trial of batoclimab in Graves disease in Summer 2025.
• Immunovant plans to initiate a potentially registrational trial evaluating IMVT-1402 in Sjogren's disease and a second potentially registrational trial in Graves disease in Summer 2025.
• Priovant expects topline data from the Phase 3 trial of brepocitinib in dermatomyositis in 2H 2025.
• Immunovant expects topline data from Phase 3 trials of batoclimab in thyroid eye disease in 2H 2025.
• Pulmovant expects topline data from the Phase 2 trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease in 2H 2026.
• Priovant expects topline data from the Phase 2 trial in cutaneous sarcoidosis in 2H 2026.
• Immunovant expects initial results from open label period 1 of potentially registrational trial in ACPA+ difficult-to-treat rheumatoid arthritis in 2026.
• Immunovant expects topline data from Phase 2 trial in cutaneous lupus erythematosus in 2026.
• Priovant expects topline data from Phase 3 trials in non-infectious uveitis in 1H 2027.
• Immunovant expects topline data from potentially registrational trial in ACPA+ difficult-to-treat rheumatoid arthritis in 2027.
• Immunovant expects topline data from potentially registrational trial in Graves disease in 2027.
• Immunovant expects topline data from potentially registrational trial in myasthenia gravis in 2027.
• Immunovant expects topline data from potentially registrational trial in Sjogren's disease in 2028.
• Immunovant expects topline data from potentially registrational trial in chronic inflammatory demyelinating polyneuropathy in 2028.
• The company will make a final decision about future development and regulatory submissions for batoclimab based on aggregate information available at the time.
• The court in the U.S. Moderna case plans to update the timing for the summary judgment phase and jury trial.
• The Markman hearing ruling in the Pfizer/BioNTech case is potentially expected in 2025.
• The company will continue to assess the realizability of deferred tax assets at each balance sheet date.
• The company will continue to assess the impact of changes in tax laws and interpretations on its business.
• The company expects to hire additional personnel and implement procedures to address public company regulatory requirements.
• The company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Drug Development, Clinical Trials, SEC Filing, 10-K, Roivant Sciences, ROIV, Vant Model, Brepocitinib, IMVT-1402, Batoclimab, Mosliciguat, TYK2/JAK1 inhibitor, FcRn inhibitor, sGC activator, Dermatomyositis, Non-Infectious Uveitis, Cutaneous Sarcoidosis, Graves Disease, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Rheumatoid Arthritis, Sjogren's Disease, Cutaneous Lupus Erythematosus, Pulmonary Hypertension, Interstitial Lung Disease, Patent Litigation, Moderna, Pfizer, BioNTech, Organon, Telavant, Divestiture, Share Repurchase, Financial Results, Research and Development, General and Administrative, Intellectual Property, Regulatory Approval, FDA, EMA, MHRA, Cybersecurity, Corporate Governance, Risk Management, Biotechnology